On February 6, Yangpu Medical , which was listed on the GEM of the Shenzhen Stock Exchange, has new developments.
Yangpu Medical intends to issue no more than 60 million shares to no more than 5 specific targets, and raise funds of no more than 600 million yuan. It plans to invest in 3 medical product projects and the Yizhang County Chinese Medicine Hospital Relocation (PPP) project. The company's stock will resume trading on February 7.
In 1996, Yangpu Medical was established in Guangzhou. Starting from medical equipment, from specimen experts to nursing experts, from technology to services, it is now set to increase by 600 million. What areas will be placed?
Guangzhou Yangpu Medical
Starting with medical devices, this 18-year transcript
In August 1996, when Deng Guanhua was 30 years old, he went to Guangdong to participate in the establishment of Yangpu Medical, engaged in the research and development and manufacturing of in vitro diagnostic medical devices, and served as chief engineer, deputy general manager, general manager and chairman. He used to be the director of the Institute of Chemistry and Chemical Engineering of Wuhan University. His research interests include electrode process kinetics, intermediates, and human venous blood variability.
At the beginning of the business, Deng Guanhua was extremely poor. He once led a monthly salary of 1,000 yuan. He spent the money on the provincial bus and even walked when he went to the hospital.
On December 25, 2009, after more than ten years of development, Yangpu Medical was successfully listed on the GEM of the Shenzhen Stock Exchange. It was the first medical device listed company in Guangdong at the time of its issue price of RMB 25 per share. On the first day of listing, it hit a record high of 40 yuan. Deng Guanhua has worked hard, and the market value of the 17.02 million shares of Yangpu Medical held immediately exceeded 400 million yuan.
Although Yangpu Medical started from medical equipment, it has been working hard on internal strength. Based on independent research and development and innovation, it has established the key laboratory of “Research on Blood Compatibility of Medical Materials†in Guangdong Province, and has undertaken a number of 863 programs and clinical immunodiagnosis. Major projects such as system research and development, special funds for industry-university-research cooperation in Guangdong Province, and industrial platform construction projects.
In the past 18 years, Yangpu Medical has owned 8 core proprietary technologies and 65 scientific research patents for blood collection, and upgraded the third-generation vacuum blood collection system of the main products to the most comprehensive and special inspection tube for domestic and foreign counterparts. The highest-end, high-quality product with the best quality and speed of serum preparation. Yangpu Medical is the third-generation vacuum blood collection system definition, the leader of the pre-analytical variation control of specimens, and the only domestic vacuum collection system that has passed the US FDA registration.
At present, Yangpu Medical's medical device sales channels have expanded to more than 90 countries and regions around the world, providing support for a wide range of products, technologies and services in nearly 1,000 medical colleges, research institutes, hospitals and diagnostic laboratories.
As of September 30, 2016, Yangpu Medical's operating income was 358.93 million yuan, and the net profit attributable to shareholders of the parent company was 2,151,938,380 yuan, a decrease of 25.7265% compared with the same period of last year. The basic earnings per share was 0.07 yuan. .
Omega-3 Fish Oil,Fish Oil 10/50 Tg,Omega 3 Fish Oil,10/50 Tg Fish Oil
ZHOUSHAN SINOMEGA BIOTECH ENGINEERING CO.,LTD , https://www.sinomegabiotech.com